Study scope

This campaign examines cell-surface targets in pMMR left-sided mucinous colon cancer. Public disease, cell-expression, protein, and structure records inform the target review.

Disease and research question

Identify cell-surface proteins and binding sites for molecule screening or protein-binder design.

The campaign focuses on high-risk, node-positive stage III pMMR left-sided mucinous colon cancer. Its research scope includes malignant epithelial cells in primary, nodal, metastatic, residual, and treatment-persistent states.

Sample groups in the RNA analysis

477 source samplesTwo separate comparisons

Tumor type

Mucinous: 37
Other tumor types: 440

Tumor location

Selected left sites: 92
Other sites: 385

2 samples meet both conditions; the recorded ranking rule requires at least 10. Samples were selected using the recorded microsatellite-stability score thresholds.

RNA measurements by target and sample group

RNA comparisons

These data compare tumor RNA expression by mucinous histology and colorectal location. The analysis uses score thresholds to classify samples as microsatellite stable (MSS). Surface-protein abundance and patient pMMR status require their own measurements.

Colorectal Adenocarcinoma (TCGA, PanCancer Atlas) · 184 targets mapped · 1 unresolved

Study and cohort definitions

Source study: Colorectal Adenocarcinoma (TCGA, PanCancer Atlas)
Study ID: coadread_tcga_pan_can_atlas_2018
RNA measurement: batch-normalized RNA Seq V2 RSEM
Molecular profile: coadread_tcga_pan_can_atlas_2018_rna_seq_v2_mrna
Overlay timestamp: 2026-09-04
Targets mapped: 184
Targets unresolved: 1
MSS-proxy rule: MANTIS score <0.4 when present; otherwise MSIsensor score <10

Histology field: CANCER_TYPE_DETAILED
Mucinous field value: Mucinous Adenocarcinoma of the Colon and Rectum
Site field: ICD_O_3_SITE
Selected site codes: C18.5, C18.6, C18.7, C19.9
Site-code meaning: splenic flexure, descending colon, sigmoid colon, or rectosigmoid code
MSS-proxy interpretation: public-cohort MSS proxy; not a patient-level pMMR measurement

MSI_SCORE_MANTIS<0.4: 448
MSI_SENSOR_SCORE<10: 29

The comparison groups contain samples outside the exact histology value or selected site codes, including unclassified records.

Each value is the recorded log₂ ratio of cohort medians, with 1 added to each median before division. Positive values mean higher RNA in the mucinous or selected left-site group; zero means equal adjusted medians. Expand a target to inspect its measured sample counts.

Target Mucinous / other histology · log₂ Selected left / other site · log₂ Per-target measurements

CEACAM6T-ENSG00000086548

-0.295

+0.372

Sample counts and RNA summaries

Recorded per-target cohort summaries
Source cohort	Measured samples	Expected samples	Coverage fraction	Median RSEM	25th percentile	75th percentile	Detected fraction
Mucinous histology `mss_proxy_mucinous`	37	37	1.0	24184.2553	11975.6	54167.9	1.0
Other histology `mss_proxy_nonmucinous`	438	440	0.995455	29668.27465	16774.65	52530.122675	1.0
Selected left colorectal sites `mss_proxy_left_colorectal`	90	92	0.978261	35576.8	19972.3169	52880.375	1.0
Outside selected site codes `mss_proxy_other_site`	385	385	1.0	27495.7	15331.3	52705.8	1.0
Mucinous and selected left sites `joint_mss_proxy_mucinous_left`	2	2	1.0	50501.22	29221.03	71781.41	1.0